TCR2 THERAPTCS (TCRR)
(Delayed Data from NSDQ)
$16.92 USD
+0.13 (0.77%)
Updated May 3, 2019 04:13 PM ET
After-Market: $17.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TCRR]
Reports for Purchase
Showing records 1 - 20 ( 162 total )
Industry: Medical - Drugs
Dropping Coverage of TCRR Ahead of Merger with ADAP
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Can These TRUCs ADAPt to Their New Environment?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
TCR2 Slated to Merge With Adaptimmune; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Updated Phase 1 Gavo-Cel Results Remain Encouraging, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
TCRR Delivers More Data Packages from the Gavo-cel TRuC
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Additional Solid Tumor Responses in Phase I Update. Phase II Ongoing.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
A Catalyst-Rich 2H22; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R